YESAMLO is indicated in the treatment of hypertension.
YESAMLO inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.
Peak plasma concentrations produce between 6 and 12 hours. Bioavailability: between 64 and 90%. YESAMLO is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Elimination half-life: 30–50 hours. Steady-state plasma levels of YESAMLO reach after 7 to 8 days of consecutive daily dosing.
The usual initial antihypertensive oral dose is 2.5 mg once daily, and the maximum dose is 5 mg once daily. Most patients will require 5 mg for adequate effect. Small, fragile, or elderly patients, or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding to other antihypertensive therapy. Adjust dosage according to blood pressure goals. In general, wait 7 to 14 days between titration steps. Titrate more rapidly, however, if clinically warranted, provided the patient is assessed frequently. *Except in dosing: reduce to half the dose of YESAMLO in both indication
YESAMLO 2.5 (S-amlodipine 2.5 mg): 10 x 10s YESAMLO 5 (S-amlodipine 5 mg): 10 x 10s